4.855

0.52% +0.025

Synaptogenix Inc (SNPX)

Overview News Price History Financials Discussions Forecast Stock Split

Synaptogenix Inc stock is currently priced at $4.855, with a 24-hour trading volume of 38,551. It has seen a +0.52% increased in the last 24 hours and a +2,540% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.73 pivot point. If it approaches the $5.09 resistance level, significant changes may occur.

Previous Close:

$4.83

Open:

$4.95

24h Volume:

38,551

Market Cap:

$5.24M

Revenue:

Net Income/Loss:

$-560.20K

P/E Ratio:

-3.3483

EPS:

-1.45

Net Cash Flow:

$-6.90M

1W Performance:

+10.02%

1M Performance:

+2,540%

6M Performance:

+1,583%

1Y Performance:

+478.87%

1D Range:

$4.75

$5.18

52W Range:

$0.1411

$6.217

Synaptogenix Inc Stock (SNPX) Company Profile

Name

Synaptogenix Inc

Sector

Healthcare (1193)

Industry

Biotechnology (685)

Phone

973 242 0005

Address

1185 Avenue of the Americas, 3rd Floor, New York

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SNPX's Discussions on Twitter

Synaptogenix Inc Stock (SNPX) Latest News

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Benzinga

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Sintx Technologies Shares Are Trading Higher By Over 39%; Here Are 20 Stocks Moving Premarket

Benzinga

Synaptogenix Inc Stock (SNPX) Financials Data

Synaptogenix Inc (SNPX) Net Income 2024

SNPX net income (TTM) was -$560.20 thousand for the quarter ending September 30, 2023, a +96.08% increase year-over-year.

Synaptogenix Inc (SNPX) Cash Flow 2024

SNPX recorded a free cash flow (TTM) of -$6.90 million for the quarter ending September 30, 2023, a +34.19% increase year-over-year.

Synaptogenix Inc (SNPX) Earnings per Share 2024

SNPX earnings per share (TTM) was -$1.05 for the quarter ending September 30, 2023, a +49.03% growth year-over-year.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.